Research

Joint Programming Initiative on AMR

Background

The Joint Programming Initiative on Antimicrobial Resistance (JPI AMR) was set up to streamline the European research efforts in AMR by joint planning, implementation and evaluation of national research programmes.

It consists of 19 participating countries (Belgium Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Israel, Italy, the Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey and the United Kingdom) of which the MRC is the UK representative. The JPI AMR will develop integrated approaches to pursue unique world-class research on AMR that will be translated into new prevention and intervention strategies that improve the public health and wellbeing of populations, and delivers economic and societal benefit throughout Europe and beyond. An important element of the mission of the JPI AMR will be to connect to and collaborate with the different stakeholders involved in its mission. This JPI aims to coordinate the European Union (EU) research activities on AMR through the Strategic Research Agenda and the EU funding instruments; specifically Framework Programme 8 (Horizon 2020) with calls relevant to AMR, Innovative Medicines Initiative (IMI) and the ERA-NET scheme (ERA-NET on AMR).

The Strategic Research Agenda

JPI AMR has been developing a Strategic Research Agenda (SRA) to provide a framework through which co-operative activities align with or link to national investments to achieve increased impact and potential new funding.

The SRA focuses on antibiotic resistance particularly among bacteria that can cause life-threatening infection in hospitals and primary care settings. Six priority topics were identified and described in the SRA. Together, these priority topics cover all relevant aspects of AMR and, if implemented, can eventually lead to a lower, smarter use of antibiotics in veterinary, food production and clinical settings and to a significant reduction of the risk that antibiotic-resistance poses to public health.

The priority topics are:

  1. Development of novel antibiotics and alternatives for antibiotics – from basic research to the market. This includes the improvement of current antibiotics and treatment regimens, the development of new antibiotics and therapeutic alternatives to antibiotics.
  2. The improvement of diagnostics and the development of novel (rapid) diagnostics to stimulate better use of current  antibiotics and support the development and use of new antibiotics and alternatives to antibiotics.
  3. The establishment of an international, standardized surveillance programme for AMR and antibiotic use in human and agricultural settings.
  4. A comprehensive, multi-disciplinary understanding of the transmission mechanisms by which antibiotic resistance can spread between bacterial populations and between different (animal and human) reservoir and to translate this knowledge into the development of evidence-based strategies to minimize the spread of resistance.
  5. The assessment of the contribution of pollution of the environment with antibiotics, antibiotic residues and resistant bacteria on the spread of AMR and the development of strategies to minimize environmental contamination by antibiotics and resistant bacteria.
  6. The study of preventive and control interventions that focus on improved antibiotic stewardship, compliance and prevention of transmission of AMR and to determine and improve their efficacy.
     

Mapping Research Activities in AMR

To support and coordinate the action of the JPI AMR and its SRA, a European mapping exercise is currently underway, led by the MRC, to get an overview of the different nationally and EU-funded programmes related to AMR.

The mapping will function as a mechanism to insure that research funded by different countries and bodies is more synergistic. The mapping will also help identify the gaps and research opportunities within the EU-wide AMR portfolio and assist in decision making for the different funding bodies. While attention will naturally be focused on addressing research at national and European levels, it is recognised that the unmet clinical need and societal impact of AMR is a global issue. Canada has now become a full member and is involved in the mapping portfolio. More countries will be invited to join in the discussions to further strengthen the worldwide research efforts in this area.

Lancet Infectious Diseases Publication - Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis

JPIAMR Funded Research 

JPIAMR 1st Joint Call: InnovaResistance (Call now closed) Innovative approaches to address antibacterial resistance - was launched at the end of January 2014.

JPIAMR 3rd Joint Call: JPI-EC-AMR ERA-NET Co-fund Call on Transmission Dynamics (Call now closed) - was launched in mid- January 2016.

JPIAMR 4th Joint Call: Call for Transnational Working Groups (Call closed June 6th 2016) - was launched in April 2016.

For more information on funded projects, click here

For more information on the UK funded projects, click here

Supported by 12 countries, its aim is to combine the resources, infrastructures, and research strengths of multiple countries in order to overcome antibiotic resistance. The goal is to foster multinational translational research collaborations that can accomplish more than individual countries working independently, leading to improved control of bacterial infections. Final decision on successful proposals will be made October 2014.

To view supported grants please visit the Joint Programme Initiative on Antimicrobial Resistance website.

Other activities